Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis

References

• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699.
   PubMed Web of Science ®Google Scholar
• Bruni C, Frech T, Manetti M, et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? Front Immunol. 2018;9:2045.
   PubMed Web of Science ®Google Scholar
• Maciejewska M, Sikora M, Maciejewski C, Alda-Malicka R, Czuwara J, Rudnicka L. Raynaud’s phenomenon with focus on systemic sclerosis. J Clin Med. 2022;11(9):2490.
   PubMed Web of Science ®Google Scholar
• Lechartier B, Humbert M. Pulmonary arterial hypertension in systemic sclerosis. Presse Med. 2021;50(1):104062.
   PubMed Web of Science ®Google Scholar
• Chrabaszcz M, Małyszko J, Sikora M, et al. Renal involvement in systemic sclerosis: an update. Kidney Blood Press Res. 2020;45(4):532–548.
   PubMed Web of Science ®Google Scholar
• Polito P, Zanatta E, Felicetti M, et al. Skin ulcers in systemic sclerosis: correlation with clinical phenotype in a monocentric cohort from the north-east of Italy. Clin Exp Rheumatol. 2020;38(3):148–153.
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2008;67(1):120–123.
   PubMed Web of Science ®Google Scholar
• Shenavandeh S, Sepaskhah M, Dehghani S, Nazarinia M. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Clin Rheumatol. 2022;41(1):95–104.
   PubMed Web of Science ®Google Scholar
• Pattanaik D, Brown M, Postlethwaite AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res. 2011;4:105–125.
   PubMedGoogle Scholar
• Kostov K. The causal relationship between endothelin-1 and hypertension: focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life. 2021;11(9):986.
   PubMedGoogle Scholar
• Szczepanska-Sadowska E, Czarzasta K, Cudnoch-Jedrzejewska A. Dysregulation of the renin-angiotensin system and the vasopressinergic system interactions in cardiovascular disorders. Curr Hypertens Rep. 2018;20(3):19.
   PubMed Web of Science ®Google Scholar
• Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29(7):367–374.
   PubMed Web of Science ®Google Scholar
• Stawski L, Han R, Bujor AM, Trojanowska M. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther. 2012;14(4):R194.
   PubMed Web of Science ®Google Scholar
• Miziolek B, Bergler-Czop B, Kucharz E, et al. Significance of the angiotensin I/angiotensin II/angiotensin-(1-7) axis in the pathogenesis of systemic sclerosis. J Eur Acad Dermatol Venereol. 2020;34(3):558–564.
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp. 2015;63(1):41–52.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pascual F, Busnadiego O, Gonzalez-Santamaria J. The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? Life Sci. 2014;118(2):156–164.
   PubMed Web of Science ®Google Scholar
• Riemekasten G, Philippe A, Näther M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 2011;70(3):530–536.
   PubMed Web of Science ®Google Scholar
• Szczepanska-Sadowska E. The heart as a target of vasopressin and other cardiovascular peptides in health and cardiovascular diseases. Int J Mol Sci. 2022;23(22):14414.
   PubMed Web of Science ®Google Scholar
• Szczepanska-Sadowska E, Zera T, Sosnowski P, Cudnoch-Jedrzejewska A, Puszko A, Misicka A. Vasopressin and related peptides; potential value in diagnosis, prognosis and treatment of clinical disorders. Curr Drug Metab. 2017;18(4):306–345.
   PubMed Web of Science ®Google Scholar
• Lukaszyk E, Malyszko J. Copeptin: pathophysiology and potential clinical impact. Adv Med Sci. 2015;60(2):335–341.
   PubMed Web of Science ®Google Scholar
• Mu D, Cheng J, Qiu L, Cheng X. Copeptin as a diagnostic and prognostic biomarker in cardiovascular diseases. Front Cardiovasc Med. 2022;9:901990.
   PubMed Web of Science ®Google Scholar
• Niemczyk S, Niemczyk L, Zmudzki W, et al. Copeptin blood content as a diagnostic marker of chronic kidney disease. Adv Exp Med Biol. 2018;1096:83–91.
   PubMed Web of Science ®Google Scholar
• Rojas-Humpire R, Soriano-Moreno DR, Galindo-Yllu B, Zafra-Tanaka JH. Association between copeptin and metabolic syndrome: a systematic review. J Nutr Metab. 2022;2022:5237903.
   PubMed Web of Science ®Google Scholar
• Pawlik KK, Bohdziewicz A, Chrabaszcz M, et al. Biomarkers of disease activity in systemic sclerosis. Wiad Lek. 2020;73(10):2300–2305.
   PubMedGoogle Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747.
   PubMed Web of Science ®Google Scholar
• Krasowska D, Rudnicka L, Dańczak-Pazdrowska A, et al. Twardzina układowa – rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego. Część 1: diagnostyka i monitorowanie. Dermatol Rev. 2017;104(5):483–498.
   Google Scholar
• Saketkoo LA, Frech T, Varjú C, et al. A comprehensive framework for navigating patient care in systemic sclerosis: a global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Pract Res Clin Rheumatol. 2021;35(3):101707.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205.
   PubMed Web of Science ®Google Scholar
• Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2(1):11–18.
   PubMed Web of Science ®Google Scholar
• Pauling JD, Reilly E, Smith T, Frech TM. Factors influencing raynaud condition score diary outcomes in systemic sclerosis. J Rheumatol. 2019;46(10):1326–1334.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6(10):578–587.
   PubMed Web of Science ®Google Scholar
• Dobsa L, Edozien KC. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Med. 2013;23(2):172–190.
   Web of Science ®Google Scholar
• Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106(1):107–116.
   PubMed Web of Science ®Google Scholar
• Sparapani S, Millet-Boureima C, Oliver J, et al. The biology of vasopressin. Biomedicines. 2021;9(1):89.
   PubMed Web of Science ®Google Scholar
• Nawaz I, Nawaz Y, Nawaz E, Manan MR, Mahmood A. Raynaud’s phenomenon: reviewing the pathophysiology and management strategies. Cureus. 2022;14(1):e21681.
   PubMed Web of Science ®Google Scholar
• Roca Oporto FJ, Rocha JL. Raynaud’s phenomenon triggered by the vasopressin V(2) receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren’s syndrome. Clin Kidney J. 2022;15(4):827–828.
   PubMed Web of Science ®Google Scholar
• Hayoz D, Bizzini G, Noël B, et al. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud’s phenomenon. Rheumatology. 2000;39(10):1132–1138.
   PubMed Web of Science ®Google Scholar
• Szmygin H, Szydełko J, Matyjaszek-Matuszek B. Copeptin as a novel biomarker of cardiometabolic syndrome. Endokrynol Pol. 2021;72(5):566–571.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Manetti M, Bruni C, et al. The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? Arthritis Res Ther. 2017;19(1):162.
   PubMedGoogle Scholar
• Waszczykowska A, Goś R, Waszczykowska E, Dziankowska-Bartkowiak B, Podgórski M, Jurowski P. The role of angiogenesis factors in the formation of vascular changes in scleroderma by assessment of the concentrations of VEGF and sVEGFR2 in blood serum and tear fluid. Mediators Inflamm. 2020;2020:7649480.
   PubMed Web of Science ®Google Scholar
• Bellando Randone S, George J, Mazzotta C, et al. Angiostatic and angiogenic chemokines in systemic sclerosis: an overview. J Scleroderma Relat Disord. 2017;2(1):1–10.
   Google Scholar
• Ripoll GV, Garona J, Pifano M, Farina HG, Gomez DE, Alonso DF. Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. Breast Cancer Res Treat. 2013;142(1):9–18.
   PubMed Web of Science ®Google Scholar
• Garona J, Sobol NT, Solernó LM, Alonso DF. Potential use of desmopressin during hepatic resection for colorectal liver metastases. J Surg Res. 2019;237:1–2.
   PubMed Web of Science ®Google Scholar
• Hughes M, Bruni C, Ruaro B, Confalonieri M, Matucci-Cerinic M, Bellando-Randone S. Digital ulcers in systemic sclerosis. Presse Med. 2021;50(1):104064.
   PubMed Web of Science ®Google Scholar
• Potier L, Roussel R, Marre M, et al. Plasma copeptin and risk of lower-extremity amputation in type 1 and type 2 diabetes. Diabetes Care. 2019;42(12):2290–2297.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Schioppo T, Allanore Y, et al. Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum. 2019;48(4):686–693.
   PubMed Web of Science ®Google Scholar
• Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004;33(4):253–256.
   PubMed Web of Science ®Google Scholar
• Holmes SW, Horton EW, Main IHM. The effect of prostaglandin E1 on responses of smooth muscle to catechol amines, angiotensin and vasopressin. Br J Pharmacol Chemother. 1963;21(3):538–543.
   PubMed Web of Science ®Google Scholar
• Knepel W, Nutto D, Vlaskovska M, Kittel C. Inhibition by prostaglandin E2 of the release of vasopressin and beta-endorphin from rat pituitary neurointermediate lobe or medial basal hypothalamus in vitro. J Endocrinol. 1985;106(2):189–195.
   PubMed Web of Science ®Google Scholar
• Machida K, Wakamatsu S, Izumi Y, et al. Downregulation of the V2 vasopressin receptor in dehydration: mechanisms and role of renal prostaglandin synthesis. Am J Physiol. 2007;292(4):F1274–F1282.
   Google Scholar
• Graßhoff H, Fourlakis K, Comdühr S, Riemekasten G. Autoantibodies as biomarker and therapeutic target in systemic sclerosis. Biomedicines. 2022;10(9):2150.
   PubMed Web of Science ®Google Scholar
• Gargiulo M, Pérez N, Khoury M, et al. Anti-RNA polymerase III antibodies in systemic sclerosis: multicentric study from Argentina. Reumatol Clin. 2021;18(6):368–373.
   PubMedGoogle Scholar